1. Discovery and Development (1950s)
• Early 1950s: Researchers were exploring sulfonamide-based compounds to find treatments for hypertension and edema.
• 1957: A team at Merck & Co., led by Dr. Karl H. Beyer Jr., James Sprague, and John Baer, synthesized a new class of compounds based on benzothiadiazine, which exhibited potent diuretic effects.
• The prototype compound, chlorothiazide, was found to promote sodium and water excretion while lowering blood pressure.
2. FDA Approval and Commercialization
• 1958: Chlorothiazide (brand name Diuril) became the first thiazide diuretic approved by the FDA.
• It was revolutionary, offering an oral alternative to the injectable mercurial diuretics previously used.
3. Expansion and New Derivatives
• Following chlorothiazide, hydrochlorothiazide was developed—this became more widely used due to its higher potency and better absorption.
• Other derivatives, such as bendroflumethiazide, metolazone, and indapamide, were developed with varying potencies and durations of action.
4. Clinical Impact
• Thiazides became foundational in the management of hypertension, heart failure, and edematous states.
• Studies like the ALLHAT trial (2002) confirmed the efficacy of thiazides (especially chlorthalidone) as first-line agents in hypertension.
5. Current Use
• Thiazide and thiazide-like diuretics remain among the most commonly prescribed medications for hypertension.
• They are often used in combination with ACE inhibitors, ARBs, or calcium channel blockers.
Thiazide diuretics were developed during the 1950s when chemists and physiologists at Merck Sharpe and Dohme tested derivatives of sulfonamide-based carbonic anhydrase inhibitors, with the goal of discovering drugs that enhance the excretion of sodium with chloride, rather than sodium bicarbonate*.
Indication
1. Acetazolamide + Salicylates:
• Increases free acetazolamide → toxicity and metabolic acidosis.
2. NSAIDs + Diuretics:
• Reduce the effectiveness of diuretics and antihypertensive drugs.
• Can cause acute renal failure, especially with loop or thiazide diuretics.
3. Loop Diuretics + Ototoxic Drugs (e.g., aminoglycosides):
• Increased risk of ototoxicity (hearing loss).
4. Hypokalemia + Digoxin:
• Increases risk of fatal arrhythmias.
• Highest risk with loop diuretics and thiazides (especially hydrochlorothiazide).
5. Thiazides + Calcium/Vitamin D:
• Increases calcium retention.
6. Thiazides + Lithium:
• Increases lithium toxicity.
7. Potassium-Sparing Diuretics + RAAS Inhibitors (ACEIs, ARBs, Beta-blockers, NSAIDs)
• Risk of hyperkalemia
Brand names
Bendroflumethiazide
Brinaldix
Chlorothiazide
Chlorthalidone
Metolazone
Bendroflumethiazide
Brinaldix
• Lozol • Natrilix
Averothiazide
Chlorothiazide
Chlorthalidone
Metolazone
https://pmc.ncbi.nlm.nih.gov/articles/PMC8109680/
https://pubmed.ncbi.nlm.nih.gov/20798254/
https://www.ncbi.nlm.nih.gov/books/NBK532918/
https://go.drugbank.com/drugs/DB00999
https://www.drugs.com/drug-class/thiazide-diuretics.html
https://drive.google.com/file/d/1RFDGWxl3WMynjsZVPYCsp1lKEVhkkgou/view?usp=drive_link
https://www.ncbi.nlm.nih.gov/books/NBK557838/
https://www.ncbi.nlm.nih.gov/books/NBK532918/
https://www.ncbi.nlm.nih.gov/books/NBK9626/